Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022
PR Newswire
April 4, 2022 β 08:00 CST
UNLOCK DATA Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech